New drug duo targets aggressive lung cancer after standard treatments fail
NCT ID NCT07501169
Summary
This study is testing a new combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has gotten worse after their first treatment. The goal is to see if this two-drug approach can shrink tumors and control the cancer better than current options. The trial will enroll about 33 patients to check how well the treatment works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
Sichuan, Chengdu, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.